NTLAIntellia opens the tap
Intellia Therapeutics just priced an underwritten public offering of 16.7 million shares of common stock at $10.75 apiece. Translation: the biotech is choosing the classic “raise cash now, explain dilution later” playbook.
What’s in the box?
The company expects gross proceeds of roughly $180 million before underwriting discounts and expenses. That’s enough to give the balance sheet a boost, but it also means existing shareholders are getting a slightly smaller slice of the pie.
- 16,744,187 shares being sold
- About $180 million in gross proceeds
- A 30-day option for underwriters to buy up to 2,511,628 more shares
- All the shares are coming straight from Intellia, not a secondary seller
Why investors should care
For a company like Intellia, cash is oxygen. Gene-editing programs are expensive, timelines are long, and the market has zero patience for a biotech running on fumes. But there’s always a tradeoff: the more capital you raise, the more you dilute the people already holding the bag.
Big picture
This isn’t exactly a victory lap, but it is a practical move. Intellia gets more runway, and investors get to decide whether the science is exciting enough to tolerate the dilution tax.